Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages



News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

FDA approves Promacta for severe aplastic Anaemia-GSK


The FDA has approved a supplemental ...

EU Commission approves Velphoro for treatment of Hyperphosphatemia in CKD patients- Vifor Fresenius Renal Pharma


Velphoro (sucroferric oxyhydroxide) ...

European Commission approves Daklinza for treatment of chronic Hepatitis C- BMS


Bristol-Myers Squibb Company ...

Medtronic acquires Sapiens Steering Brain Stimulation for $200 million


Medtronic, Inc. announced that it has ...

FDA approves Zorvolex for Osteoarthritis Pain-Iroko Pharma


The FDA has approved Zorvolex ...

Roche to acquire InterMune Inc. for $8.3 Billion


Roche and InterMune, Inc. announced they ...

FDA approves Triumeq triple therapy for HIV-1 Infection- Viiv HealthCare


ViiV Healthcare announced that the ...

Recent Updates


Clinical Guidelines

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Guidelines on Upper Urinary Tract Urothelial Cell Carcinomas

Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas

Medical Journals

Enhanced Recovery After Elective Coronary Revascularization Surgery With Minimal Versus Conventional Extracorporeal Circulation: A Prospective Randomized Study

Patellofemoral Joint Loading During Stair Ambulation in People With Patellofemoral Osteoarthritis

Androgen-deprivation Therapy and Diabetes Control Among Diabetic Men with Prostate Cancer

Platelets express and release osteocalcin and co-localize in human calcified atherosclerotic plaques

epgonline.org Social